
1. antimicrob agents chemother. 2018 dec 21;63(1). pii: e01735-18. doi:
10.1128/aac.01735-18. print 2019 jan.

inhibition cytomegalovirus replication extended-half-life synthetic
ozonides.

wang y(#)(1), mukhopadhyay r(#)(1), roy s(1), kapoor a(1), su yp(1), charman
sa(2), chen g(2), wu j(3), wang x(3), vennerstrom jl(3), arav-boger r(4).

author information: 
(1)department pediatrics, johns hopkins university school medicine,
baltimore, maryland, usa.
(2)centre drug candidate optimization, monash institute pharmaceutical
sciences, victoria, australia.
(3)department pharmaceutical sciences, college pharmacy, university of
nebraska medical center, omaha, nebraska, usa.
(4)department pediatrics, johns hopkins university school medicine,
baltimore, maryland, usa rboger@mcw.edu.
(#)contributed equally

artesunate (as), semisynthetic artemisinin approved malaria therapy,
inhibits human cytomegalovirus (hcmv) replication vitro, therapeutic
success humans variable. hypothesized short vivo
half-life may contribute different treatment outcomes. tested
novel synthetic ozonides longer half-lives hcmv vitro mouse
cytomegalovirus (mcmv) vivo screening activities four ozonides
against pp28-luciferase-expressing hcmv towne recombinant identified oz418 to
have best selectivity; effective concentration inhibiting viral growth by
50% (ec50) 9.8 ± 0.2 µm, cytotoxicity noninfected human fibroblasts
(the concentration inhibiting cell growth 50% [cc50]) 128.1 ± 8.0 µm. in
plaque reduction assays, oz418 inhibited hcmv tb40 concentration-dependent
manner well ganciclovir (gcv)-resistant hcmv isolate. combination 
oz418 gcv synergistic hcmv inhibition vitro virus inhibition by
oz418 occurred early stage dependent cell density the
time infection. oz418 treatment reversed hcmv-mediated cell cycle progression 
and correlated reduction hcmv-induced expression prb, e2f1, and
cyclin-dependent kinases 1, 2, 4, 6. mcmv model, once-daily oral
administration oz418 significantly improved efficacy mcmv compared
to twice-daily oral as. parallel pharmacokinetic study single
oral dose oz418 showed prolonged plasma half-life higher unbound
concentrations oz418 unbound concentrations as. summary, ozonides
are proposed potential therapeutics, alone combination gcv, 
hcmv infection humans.

copyright © 2018 american society microbiology.

doi: 10.1128/aac.01735-18 
pmcid: pmc6325236
pmid: 30373792  [indexed medline]

